GU Cancers 2023 | Surgery after immunotherapy for renal cell carcinoma

Mark Wayne Ball, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses the role of surgery for metastatic kidney cancer in the era of immunotherapy. Post-hoc analyses of Phase I trials have indicated that patients who achieve a complete response (CR) with immunotherapy are those who have undergone surgery. Additionally, retrospective studies have suggested improved overall-survival (OS) in patients who undergo either upfront surgery or consolidative surgery following immunotherapy. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.